All In Biotech

Drug Trial Radar · NCT06364072

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or Severe Pain, in an Acute Care Setting

Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

May 27, 2024

Primary completion

May 9, 2025

Study completion May 9, 2025

Sponsor

Lead sponsor
Cessatech A/SIndustry
Sponsor type
Industry
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children.

Conditions

  • Pain

Interventions

  • CT001Drug

    Intranasal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SedationTime frame: At baseline and 10, 15, 20, 30, 45 and 60 min after first IMP administration. If a second IMP dose was needed, sedation score was performed at the timepoints relative to first IMP administration.
  2. Respiratory DepressionTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
  3. Peripheral Oxygen SaturationTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
  4. Cardiovascular StabilityTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
  5. Number of Reported Adverse EventsTime frame: Through study completion; up to 7 days
  6. Number of Adverse Events (AEs) Reported Per ParticipantTime frame: Through study completion; up to 7 days
  7. Local Nasal IrritationTime frame: 30 and 60 min post IMP administration
  8. Analgesic EffectTime frame: At baseline and at 15 and 30 min post first IMP dose

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP) -

    Madrid, Spain

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, Spain

  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.